Design of a multicenter trial to evaluate long-term life-style intervention in adults with high-normal blood pressure levels. Trials of hypertension prevention (phase II)

Patricia R. Hebert, Robert J. Bolt, Nemat O. Borhani, Nancy R. Cook, Jerome D. Cohen, Jeffrey A. Cutler, Jack F. Hollis, Lewis H. Kuller, Norman L. Lasser, Albert Oberman, Stephen T. Miller, Cynthia Morris, Paul K. Whelton, Charles H. Hennekens

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Phase II of the Trials of Hypertension Prevention (TOHP) is a multicenter, randomized trial sponsored by the National Heart, Lung, and Blood Institute designed to test whether weight loss alone, sodium reduction alone, or the combination of weight loss and sodium reduction will decrease diastolic (DBP) and systolic blood pressure (SBP) as well as the incidence of hypertension (DBP ≥ 90 mm Hg, SBP ≥ 140 mm Hg, and/or use of antihypertensive medications) in subjects with high-normal DBP (83 to 89 mm Hg) and SBP less than 140 mm Hg at entry. These interventions were chosen for longer-term testing with end points including hypertension prevention as well as blood pressure (BP) change based on their demonstrated short-term efficacy in reducing BP in phase I of TOHP. The phase II study population is comprised of 2382 participants (1566 men and 816 women) who are 110 to 165% of desirable body weight, allocated at random to the four treatment arms using a 2 × 2 factorial design. The trial has 80% power to detect an overall treatment effect on DBP of 1.2 mm Hg for weight loss or sodium reduction and a difference of 1.6 mm Hg between the combined intervention and placebo groups. BP observers are blinded to participant treatment assignments. Participants will be followed for 3 to 4 years. This trial may have important public policy implications concerning the ability of life-style modifications to reduce BP and prevent the development of hypertension over the long term, thereby avoiding the need for drug therapy which while effective is costly and may have side effects.

Original languageEnglish (US)
Pages (from-to)130-139
Number of pages10
JournalAnnals of Epidemiology
Volume5
Issue number2
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Multicenter Studies
Life Style
Blood Pressure
Hypertension
Weight Loss
Sodium
National Heart, Lung, and Blood Institute (U.S.)
Aptitude
Public Policy
Antihypertensive Agents
Therapeutics
Placebos
Body Weight
Drug Therapy
Incidence
Population

Keywords

  • Hypertension prevention
  • sodium reduction
  • weight loss

ASJC Scopus subject areas

  • Epidemiology
  • Medicine(all)
  • Public Health, Environmental and Occupational Health

Cite this

Design of a multicenter trial to evaluate long-term life-style intervention in adults with high-normal blood pressure levels. Trials of hypertension prevention (phase II). / Hebert, Patricia R.; Bolt, Robert J.; Borhani, Nemat O.; Cook, Nancy R.; Cohen, Jerome D.; Cutler, Jeffrey A.; Hollis, Jack F.; Kuller, Lewis H.; Lasser, Norman L.; Oberman, Albert; Miller, Stephen T.; Morris, Cynthia; Whelton, Paul K.; Hennekens, Charles H.

In: Annals of Epidemiology, Vol. 5, No. 2, 1995, p. 130-139.

Research output: Contribution to journalArticle

Hebert, PR, Bolt, RJ, Borhani, NO, Cook, NR, Cohen, JD, Cutler, JA, Hollis, JF, Kuller, LH, Lasser, NL, Oberman, A, Miller, ST, Morris, C, Whelton, PK & Hennekens, CH 1995, 'Design of a multicenter trial to evaluate long-term life-style intervention in adults with high-normal blood pressure levels. Trials of hypertension prevention (phase II)', Annals of Epidemiology, vol. 5, no. 2, pp. 130-139. https://doi.org/10.1016/1047-2797(94)00057-Z
Hebert, Patricia R. ; Bolt, Robert J. ; Borhani, Nemat O. ; Cook, Nancy R. ; Cohen, Jerome D. ; Cutler, Jeffrey A. ; Hollis, Jack F. ; Kuller, Lewis H. ; Lasser, Norman L. ; Oberman, Albert ; Miller, Stephen T. ; Morris, Cynthia ; Whelton, Paul K. ; Hennekens, Charles H. / Design of a multicenter trial to evaluate long-term life-style intervention in adults with high-normal blood pressure levels. Trials of hypertension prevention (phase II). In: Annals of Epidemiology. 1995 ; Vol. 5, No. 2. pp. 130-139.
@article{cf12e19f047e4147a9e75555e63f84af,
title = "Design of a multicenter trial to evaluate long-term life-style intervention in adults with high-normal blood pressure levels. Trials of hypertension prevention (phase II)",
abstract = "Phase II of the Trials of Hypertension Prevention (TOHP) is a multicenter, randomized trial sponsored by the National Heart, Lung, and Blood Institute designed to test whether weight loss alone, sodium reduction alone, or the combination of weight loss and sodium reduction will decrease diastolic (DBP) and systolic blood pressure (SBP) as well as the incidence of hypertension (DBP ≥ 90 mm Hg, SBP ≥ 140 mm Hg, and/or use of antihypertensive medications) in subjects with high-normal DBP (83 to 89 mm Hg) and SBP less than 140 mm Hg at entry. These interventions were chosen for longer-term testing with end points including hypertension prevention as well as blood pressure (BP) change based on their demonstrated short-term efficacy in reducing BP in phase I of TOHP. The phase II study population is comprised of 2382 participants (1566 men and 816 women) who are 110 to 165{\%} of desirable body weight, allocated at random to the four treatment arms using a 2 × 2 factorial design. The trial has 80{\%} power to detect an overall treatment effect on DBP of 1.2 mm Hg for weight loss or sodium reduction and a difference of 1.6 mm Hg between the combined intervention and placebo groups. BP observers are blinded to participant treatment assignments. Participants will be followed for 3 to 4 years. This trial may have important public policy implications concerning the ability of life-style modifications to reduce BP and prevent the development of hypertension over the long term, thereby avoiding the need for drug therapy which while effective is costly and may have side effects.",
keywords = "Hypertension prevention, sodium reduction, weight loss",
author = "Hebert, {Patricia R.} and Bolt, {Robert J.} and Borhani, {Nemat O.} and Cook, {Nancy R.} and Cohen, {Jerome D.} and Cutler, {Jeffrey A.} and Hollis, {Jack F.} and Kuller, {Lewis H.} and Lasser, {Norman L.} and Albert Oberman and Miller, {Stephen T.} and Cynthia Morris and Whelton, {Paul K.} and Hennekens, {Charles H.}",
year = "1995",
doi = "10.1016/1047-2797(94)00057-Z",
language = "English (US)",
volume = "5",
pages = "130--139",
journal = "Annals of Epidemiology",
issn = "1047-2797",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Design of a multicenter trial to evaluate long-term life-style intervention in adults with high-normal blood pressure levels. Trials of hypertension prevention (phase II)

AU - Hebert, Patricia R.

AU - Bolt, Robert J.

AU - Borhani, Nemat O.

AU - Cook, Nancy R.

AU - Cohen, Jerome D.

AU - Cutler, Jeffrey A.

AU - Hollis, Jack F.

AU - Kuller, Lewis H.

AU - Lasser, Norman L.

AU - Oberman, Albert

AU - Miller, Stephen T.

AU - Morris, Cynthia

AU - Whelton, Paul K.

AU - Hennekens, Charles H.

PY - 1995

Y1 - 1995

N2 - Phase II of the Trials of Hypertension Prevention (TOHP) is a multicenter, randomized trial sponsored by the National Heart, Lung, and Blood Institute designed to test whether weight loss alone, sodium reduction alone, or the combination of weight loss and sodium reduction will decrease diastolic (DBP) and systolic blood pressure (SBP) as well as the incidence of hypertension (DBP ≥ 90 mm Hg, SBP ≥ 140 mm Hg, and/or use of antihypertensive medications) in subjects with high-normal DBP (83 to 89 mm Hg) and SBP less than 140 mm Hg at entry. These interventions were chosen for longer-term testing with end points including hypertension prevention as well as blood pressure (BP) change based on their demonstrated short-term efficacy in reducing BP in phase I of TOHP. The phase II study population is comprised of 2382 participants (1566 men and 816 women) who are 110 to 165% of desirable body weight, allocated at random to the four treatment arms using a 2 × 2 factorial design. The trial has 80% power to detect an overall treatment effect on DBP of 1.2 mm Hg for weight loss or sodium reduction and a difference of 1.6 mm Hg between the combined intervention and placebo groups. BP observers are blinded to participant treatment assignments. Participants will be followed for 3 to 4 years. This trial may have important public policy implications concerning the ability of life-style modifications to reduce BP and prevent the development of hypertension over the long term, thereby avoiding the need for drug therapy which while effective is costly and may have side effects.

AB - Phase II of the Trials of Hypertension Prevention (TOHP) is a multicenter, randomized trial sponsored by the National Heart, Lung, and Blood Institute designed to test whether weight loss alone, sodium reduction alone, or the combination of weight loss and sodium reduction will decrease diastolic (DBP) and systolic blood pressure (SBP) as well as the incidence of hypertension (DBP ≥ 90 mm Hg, SBP ≥ 140 mm Hg, and/or use of antihypertensive medications) in subjects with high-normal DBP (83 to 89 mm Hg) and SBP less than 140 mm Hg at entry. These interventions were chosen for longer-term testing with end points including hypertension prevention as well as blood pressure (BP) change based on their demonstrated short-term efficacy in reducing BP in phase I of TOHP. The phase II study population is comprised of 2382 participants (1566 men and 816 women) who are 110 to 165% of desirable body weight, allocated at random to the four treatment arms using a 2 × 2 factorial design. The trial has 80% power to detect an overall treatment effect on DBP of 1.2 mm Hg for weight loss or sodium reduction and a difference of 1.6 mm Hg between the combined intervention and placebo groups. BP observers are blinded to participant treatment assignments. Participants will be followed for 3 to 4 years. This trial may have important public policy implications concerning the ability of life-style modifications to reduce BP and prevent the development of hypertension over the long term, thereby avoiding the need for drug therapy which while effective is costly and may have side effects.

KW - Hypertension prevention

KW - sodium reduction

KW - weight loss

UR - http://www.scopus.com/inward/record.url?scp=0028917305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028917305&partnerID=8YFLogxK

U2 - 10.1016/1047-2797(94)00057-Z

DO - 10.1016/1047-2797(94)00057-Z

M3 - Article

C2 - 7795831

AN - SCOPUS:0028917305

VL - 5

SP - 130

EP - 139

JO - Annals of Epidemiology

JF - Annals of Epidemiology

SN - 1047-2797

IS - 2

ER -